Feb 17, 2017 02:48 PM IST | Source:

Buy Dishman Pharma; target of Rs 285: Systematix

Systematix is bullish on Dishman Pharma has recommended buy rating on the stock with a target price of Rs 285 in its research report dated February 14, 2017.

Buy Dishman Pharma; target of Rs 285: Systematix

Systematix's research report on Dishman Pharma

Dishman Pharma (DISH) reported weaker-than-expected revenue in 3QFY17, as part of CRAMS orders were deferred to subsequent quarters (the same is reflected in Rs743mn of inventory built up by 3Q-end), part of which would be billed in 4Q and the remaining in 1QFY18. Thus, FY17 revenue is likely to be flat yoy.


We have marginally reduced the estimates by 5%/6% for FY18e and FY19e on management’s guidance. Our revised estimates imply a revenue and profit CAGR of 7%/20% over FY16-19e. We have also reduced the target price to Rs 270 (Rs 285 earlier), which is 16x average EPS for FY18e and FY19e, though we maintain a Buy rating on the stock.

For all recommendations, click here

The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.
Follow us on
Available On